Telos Capital Management buys $2,409,468 stake in ResMed (RMD)

ResMed (RMD) : Telos Capital Management scooped up 1,773 additional shares in ResMed during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 34,172 shares of ResMed which is valued at $2,409,468.ResMed makes up approximately 1.13% of Telos Capital Management’s portfolio.

Other Hedge Funds, Including , Los Angeles Capital Management Equity Research Inc added RMD to its portfolio by purchasing 9,790 company shares during the most recent quarter which is valued at $690,293. ResMed makes up approx 0.01% of Los Angeles Capital Management Equity Research Inc’s portfolio.Glenmede Trust Co Na boosted its stake in RMD in the latest quarter, The investment management firm added 179 additional shares and now holds a total of 2,625 shares of ResMed which is valued at $183,356.Ngam Advisors reduced its stake in RMD by selling 1,350 shares or 7.23% in the most recent quarter. The Hedge Fund company now holds 17,321 shares of RMD which is valued at $1,191,685. ResMed makes up approx 0.02% of Ngam Advisors’s portfolio. Kelman-lazarov added RMD to its portfolio by purchasing 190 company shares during the most recent quarter which is valued at $12,517. ResMed makes up approx 0.01% of Kelman-lazarov’s portfolio.Cape Cod Five Cents Savings Bank boosted its stake in RMD in the latest quarter, The investment management firm added 4,225 additional shares and now holds a total of 43,935 shares of ResMed which is valued at $2,846,988. ResMed makes up approx 0.51% of Cape Cod Five Cents Savings Bank’s portfolio.

ResMed opened for trading at $70.41 and hit $70.9 on the upside on Monday, eventually ending the session at $70.6, with a gain of 0.26% or 0.18 points. The heightened volatility saw the trading volume jump to 8,29,593 shares. Company has a market cap of $9,933 M.

On the company’s financial health, ResMed reported $0.74 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus of $0.75. The company had revenue of $518.60 million for the quarter, compared to analysts expectations of $514.35 million. The company’s revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.68 EPS.

Many Wall Street Analysts have commented on ResMed. ResMed was Downgraded by Needham to ” Underperform” on Jun 27, 2016.

ResMed Inc. is engaged in the development manufacturing distribution and marketing of medical products for the diagnosis treatment and management of respiratory disorders with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders including airflow generators diagnostic products mask systems headgear and other accessories. It produces continuous positive airway pressure variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape AirSense 10 Elite AirSense 10 CPAP S9 VPAP S S9 VPAP ST S9 VPAP Adapt S9 VPAP ST-A S9 VPAP COPD and AirCurve 10 V Auto among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX Swift FX for Her Mirage FX for Her Pixi Pediatric Mask Quattro FX for Her Swift FX Bella Swift FX Nano AirFit N10 and Apnealink Air.

Leave a Reply

ResMed - Is it time to Sell?

Top Brokerage Firms are advising their investors on ResMed. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.